A n A ly s i s Carcinogenesis and neoplastic progression are mediated by the accumulation of somatic mutations. Here we report that the local density of somatic mutations in cancer genomes is highly reduced specifically in accessible regulatory DNA defined by DNase I hypersensitive sites. This reduction is independent of any known factors influencing somatic mutation density and is observed in diverse cancer types, suggesting a general mechanism. By analyzing individual cancer genomes 1 , we show that the reduced local mutation density within regulatory DNA is linked to intact global genome repair machinery, with nearly complete abrogation of the hypomutation phenomenon in individual cancers that possess mutations in components of the nucleotide excision repair system. Together, our results connect chromatin structure, gene regulation and cancer-associated somatic mutation.
Somatic mutations are a major contributor to cancer development and progression. In cancer cells, the density of somatic mutations is highly heterogeneous throughout the genome 2,3 . However, mechanisms governing the genomic distribution of somatic mutations are poorly understood. Recently, cancer genomics efforts have accumulated data on somatic mutations in tumors 4 , revealing that the relative density of somatic mutations in protein coding genes (including both introns and exons) is lower than the genome average 5 . This effect has been posited to result from transcription-coupled DNA repair (TCR) 2, 3 , which is mediated by the recruitment of the nucleotide excision repair (NER) system through RNA polymerase II (RNA Pol II) stalled at premutation lesions 6, 7 . The existence of such an effect raises the question of whether other similarly specialized repair mechanisms operate on other functionally important genomic regions.
Regulatory DNA (e.g., promoters, enhancers, insulators) active within a given cell type is characterized by hypersensitivity to DNase I 8 , resulting in DNase I hypersensitive sites (DHSs) that quantitatively reflect regulatory factor binding in place of canonical nucleosomes 9, 10 . It has long been posited that the accessibility of DNA within regulatory regions may render such regions more susceptible to DNA damage-induced mutation 11 . Evolutionary rates of sequence divergence within DHSs found in cancer genomes and primitive cells are higher than within normal differentiated cells 8 , and the density of somatic variants detected in a cultured cancer cell sample was shown to be reduced in DHSs more than the density of common singlenucleotide polymorphisms 12 . However, particularly with regard to the variability in somatic mutation rates in cancer genomes, a quantitative understanding of mutation within regulatory DNA has not been achieved, and the underlying biological mechanisms have not been explored.
RESULTS

Reduced local density of somatic mutations in DHSs
To examine mutation frequencies in regulatory DNA, we mapped DHSs genome-wide in 12 cancer cell lines, as well as normal cellular counterparts of major malignancies (Online Methods). We then analyzed whole-genome sequencing data from 34 tumor-normal pairs from seven distinct data sets: small-cell lung cancer 3 , melanoma 2 , 23 multiple myeloma 5 samples and 9 colon cancers 13 . We used published mutation data for small-cell lung cancer 3 and melanoma cell lines 2 (http://icgc.org/) and reanalyzed primary tumor data on multiple myeloma and colon cancer using MuTect 14 (http://www. broadinstitute.org/cancer/cga/mutect). These 34 cancer genomes contained 364,226 somatic point mutations in about 2.6 Gbp of sequence that could be uniquely mapped in the DHSs assay, i.e., density of 0.000139 per base pair (bp).
We observed a substantial reduction in the frequency of somatic nucleotide substitutions in DHSs compared to the genome average ( Fig. 1 and Supplementary Fig. 1 ). This reduction is highly significant and consistent across all tumors (P < 10 −36 , χ 2 test). The reduction was most prominent in the core transcription factor binding regions of DHSs marked by the maxima of DNase I cleavage intensity ( Fig. 1) .
We next confirmed that the reduction of frequency of somatic mutations in DHSs was neither the result of confounding factors influencing local variation in cancer mutation density, nor the result of sequencing and mapping biases 15 . Confounding factors may include differences between intergenic regions and genes (including both exons and introns), distance from transcription start A n A ly s i s sites 2 (Supplementary Fig. 2) , time of DNA replication during the S-phase 16 , distances to telomeres and centromeres, and local G+C content 15 . Relative density of somatic mutations also depends on sequence context, especially flanking nucleotides; different tumors exhibit different context dependencies 2, 3, 13 (Supplementary Fig. 3) . The relative density of mutations expected from the sequence context is higher in DHSs, magnifying our observation (P < 5 × 10 −181 ).
We separately analyzed the mutation density in DHSs located in intronic regions, intergenic regions and in regions proximal (<1 kb) and distal with respect to transcription start sites. In all cases, mutation density within DHSs was lower than in corresponding regions outside DHSs (P < 10 -4 ) ( Supplementary Fig. 4 ). More notably, the reduction was evident in comparison to immediately flanking 1-kb regions (P < 2.2 × 10 −16 , χ 2 test in lung, multiple myeloma and colon; P = 7.21 × 10 −13 in melanoma). Consequently, the observed reduction in the density of somatic mutations cannot be explained by a regional factor acting over long ranges 17 , such as transcription or DNA replication timing.
To rule out biases related to sequencing and mapping, for two of the cancer types (colon 13 and multiple myeloma 5 ) with available raw sequencing data, we repeated the analysis restricting it to nucleotide positions with >80% detection power based on sequencing coverage. This analysis confirmed that the density of somatic sequence alterations is significantly reduced (P < 2.2 × 10 -16 ) in DHSs compared to 1-kb flanking sequences.
To account collectively for all of the above potential confounding factors, we applied a Poisson regression model 18 . DHSs remained a significant (P < 10 -24 ) contributor to the local somatic mutation frequency on top of other factors, including DNA replication timing 19 , distance from transcription start sites, distance from the DHS itself, CpG islands status, G+C content and region type (exonic, intergenic, intronic) (Supplementary Tables 1 and 2). Because our regression analysis included neighboring windows, short-range regional dependencies could potentially inflate statistical significance. We repeated the analysis using a small subset (20%) of spatially separated windows and confirmed that DHSs remain a highly significant (P < 10 -5 ) contributor, even if only 20% of data are used ( Supplementary Tables 1 and 2) .
Notably, the effect of chromatin accessibility is monotonic and continuous and thus does not depend on the specific thresholds used to define DHSs (Supplementary Fig. 5 ). Finally, DHSs mapped in potential cells or tissues of origin (e.g., lung tissue for lung carcinoma) substantially contribute to the regression model that already includes pooled DHSs from multiple cell types ( Supplementary Tables 4-7) . This demonstrates that cell-selective chromatin architecture and not simply genomic location is the driving feature.
The observed reduction in the frequency of somatic sequence changes within DHSs might be explained by either reduced occurrence of somatic mutation or by the action of purifying selection (selective removal of alleles with deleterious effect). At present, purifying selection in cancers has not been carefully studied, so we lack information that would support or contradict the action of purifying selection. In general, population genetics and comparative genomics studies in a variety of organisms suggest that purifying selection is usually stronger in coding regions than in regulatory regions 20, 21 . To investigate the possible action of purifying selection, we compared relative mutation densities in regulatory and protein-coding regions. The average reduction (across cancers) in frequency of somatic mutations in coding sequences relative to flanking sequences is smaller than analogous reduction in DHSs compared to their flanks ( Supplementary Fig. 6 ). Furthermore, the observed reduction of mutation frequency in exons may not necessarily represent the action of purifying selection. The frequency of missense mutations is not lower than the frequency of synonymous changes (Supplementary Fig. 6 ). Thus, although it is possible that cancers may differ from evolving populations and we cannot rule out the action of purifying selection in regulatory regions, mutation attenuation seems to play a more important role.
Association with nucleotide excision repair
Relative mutation density depends on replication fidelity, levels of DNA damage or efficiency of DNA repair. The fact that the observed relative reduction of mutation density was almost entirely limited to DHSs makes it difficult to explain the reduction by an increase in global replication fidelity. It is also unlikely that more accessible DNA at DHSs would be less prone to damage than less accessible DNA elsewhere. In fact, mutation frequencies observed in model organisms are reduced by positioned nucleosomes 22, 23 , whereas the effects of nucleosome positioning on somatic mutations in cancer are relatively small and differ in whether they are positive or negative between various cancer types 15 .
Chromatin accessibility plays a major role in targeting nuclear proteins to regulatory DNA, and may provide a mechanism for preferential access by the repair machinery. Preferential activity of DNA repair proteins in accessible regulatory DNA may thus offer an explanation for the observed effect, analogous to the action of TCR in protein coding genes. We hypothesized specifically that potentiation of nucleotide excision repair (NER) and base excision repair (BER) by chromatin accessibility could be responsible for the observed relative reduction of mutation density at DHSs. The level of oxidative stress and the subsequent accumulation of lesions targeted by BER 24 is higher in malignant than in normal cells 25 . BER is an evolutionarily conserved DNA repair pathway, which starts from the recognition and excision of various base lesions by specific DNA glycosylases, followed by the processing of the resulting apurinic/apyrimidinic sites, DNA repair synthesis and ligation. Direct access of glycosylases to DNA lesions is pivotal for this repair process 26 . Not surprisingly, therefore, BER complexes preferentially assemble in nonnucleosomal regions in response to oxidative stress 27 , which naturally targets them to DHSs.
The NER pathway consists of two converging branches: global genome repair and TCR. DNA damage is first recognized by Figure 1 Relative density of somatic mutations is reduced in DHSs of all analyzed cancer genomes (lung 3 , melanoma 2 , colon 13 , multiple myeloma (MM) 5 
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A n A ly s i s the Xeroderma pigmentosum C (XPC) complex; the DNA duplex is opened by XPD and XPB helicases, followed by the excision of the damaged strand by XPF-ERCC1 and XPG nucleases, then gap filling by the replication polymerases using the intact strand as a template and finally DNA ligation 28 . A priori, NER machinery should be able to correct damaged DNA regardless of its chromatin state. A fully assembled NER complex, however, has a footprint of ~100 bp in DNA, which is significantly longer than the length of an internucleosomal linker. As a result, chromatin structure inhibits functional NER complex assembly and function [29] [30] [31] . In the case of TCR, this problem is circumvented by the fact that DNA damage is first sensed by the RNA polymerase followed by NER recruitment to an already unraveled chromatin required by the CSB and CSA proteins (reviewed in ref. 6 ). This is not the case for global genome repair, and the problem is additionally exacerbated by the fact that the damage sensor, the XPC complex, cannot bind to DNA adducts embedded in nucleosomes 32 . Thus, both lesion recognition and repair-complex assembly may be potentiated in accessible chromatin 29, 33 . The fact that roughly half of DHSs lie in intergenic regions suggests global genome repair as a more likely candidate than TCR. Notably, nucleosomal chromatin appears to inhibit global genome repair function [29] [30] [31] . Moreover, the XPC complex involved in damage recognition is inhibited from binding to lesions in nucleosomal DNA 32 . Thus, both lesion recognition and repair complex assembly may be potentiated in accessible chromatin 29, 33 . Failure of NER predisposes the body to cancer. This is best illustrated by the extreme frequency of cancers caused by exposure to sunlight in Xeroderma pigmentosum patients, evidently due to their inability to repair ultraviolet (UV) photoproducts in DNA. Mutations in NER are commonly detected in melanomas. Similar to what is observed in Xeroderma pigmentosum, most somatic mutations in melanoma cells are C:G→T:A transitions caused by UV 34 damage, which are primarily repaired by NER.
BER and NER are high-fidelity pathways, as suggested by studies showing that deactivation of these pathways leads to an increased chance of mutation from cryptic lesions or exogenous DNA damage [34] [35] [36] [37] . As was shown recently, NER defects lead to increases in the density of C:G→T:A mutations under chronic low-dose UV radiation, conditions specifically relevant to melanoma 38 .
We therefore reasoned that the relative reduction of mutation density in DHSs in individual melanoma genomes should parallel the integrity of NER pathway components. To test this, we analyzed 29 individual melanoma genomes sequenced at high coverage 1 . Figure 2 and Supplementary Table 3 show the continuous dependence of C: G→T:A mutation densities on chromatin accessibility in melanocytes in both introns and exons. We note that the observed effect is inconsistent with the recently discovered action of apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like (APOBEC) proteins [39] [40] [41] . First, APOBEC proteins act on single-stranded DNA and it is unlikely that inaccessible and untranscribed DNA would more readily adopt a single-stranded conformation than DNA in DHSs and transcribed regions. Second, action of APOBEC proteins would preferentially increase rates of C→T transitions and C→G transversions within a TCA/TCT motif. Our observation is not confined to this motif, and we did not detect a parallel effect for C→G changes (Supplementary Fig. 7) . Quantitatively, dependence of mutation density within a TCA/TCT motif on the number of DNase I cleavages was slightly lower (rather than higher) than the dependence of mutations within the TCG/TCC motif (P value for the interaction term in the regression analysis in Supplementary Fig. 7 is 2.11 × 10 −5 ). This is inconsistent with the hypothesis that action of APOBEC proteins induces the observed dependency on chromatin accessibility.
This effect was far more pronounced in the chromatin of melanocytes than in that of other cells. Furthermore, the signature of TCR activity is also observed by the higher density of C→T over G→A in the nontemplate strand 2 of exons and introns ( Supplementary  Fig. 8 ). This demonstrates that NER provides multilayer protection against UV-light damage in genes because of activity of TCR and the accessibility of chromatin to global genome repair.
Overall, 9 out of 29 melanoma genomes harbored nonsynonymous mutations in NER genes. Notably, four melanoma genomes with the The dependence is presented separately for introns and intergenic regions, and is equally present in both. Mutation densities are parametrically fitted to a spline function using a generalized additive model Poisson regression model 18 . Fig. 3 ). In three of these samples, mutation frequencies in DHSs returned close to the genomic baseline. The presence of genomes with mutations in NER genes and reduced mutation frequencies in DHSs is not surprising because NER mutations may appear late in cancer development, and some of the missense mutations may be functionally benign. This result implicates NER in observed reduction of mutation frequency in DHSs. It also provides an additional argument against selection as an explanation because purifying selection would not be expected to differentially affect melanoma samples. Eight out of the nine samples with mutations in NER pathway genes harbored mutations in major components of the NER machinery (XPG/ERCC5, XPF/ERCC4 and LIG1). These lesions would be expected to compromise both NER and TCR and therefore should affect mutation density in both DHSs and transcribed regions. Intriguingly, one of these samples also harbored a mutation in CETN2, which recognizes DNA distortions and therefore preferentially affects global genome repair function over TCR 44 . In agreement with this reasoning, three genomes carrying mutations in core subunits had a markedly smaller or negligible reduction of mutation density in transcribed regions compatible with defective TCR (Fig. 4) . Concordantly, in the genome carrying a mutation in the CETN2 gene, strong suppression of mutations in transcribed regions remained, implying that TCR function was not significantly compromised.
DISCUSSION
Taken together, our results suggest that the relative density of somatic mutations in cancer genomes is substantially suppressed in regulatory DNA, and that mutation frequency closely tracks chromatin accessibility. The hypomutational effect is highly localized and is statistically associated with intact global genome repair. The analysis of individual melanoma samples suggests that the relationship between relative mutation density and chromatin accessibility may be mediated by DNA repair. Our analysis could not completely rule out alternative explanations, such as selection for regulatory function or increased C→T deamination through enzymatic activities getting abnormal access to DNA. However, these alternatives would require an as-yet-unknown mechanism 45 to explain the association with NER in melanoma.
Our results link fine-scale chromatin accessibility with cancer mutation accumulation. Given the growing interest in the role of regulatory sequences in cancer progression 46 , these results will help provide a necessary baseline for cancer genomics projects targeting noncoding regions, similar to computational approaches used in the analysis of protein-coding genes 47 .
With the increasing amount of whole genome sequencing data, our approach can also be formalized and extended to associate mutational patterns with specific pathways, including DNA repair, DNA replication and chromatin remodeling. Mutational patterns can be treated as traits of individual tumor samples. With the large number of tumor samples available, these mutational traits can be associated with recurrent mutations in specific genes controlling mutagenesis, potentially identifying important players shaping somatic mutational landscapes.
METHODS
Methods and any associated references are available in the online version of the paper. Accession codes. These data have been deposited in GEO under accession numbers GSE29692 and GSE18927.
Note: Any Extended Data Information and Source Data files are available in the online version of the paper. Figure 4 Reduction of mutation density in DHSs and in transcribed regions. Shown for individual melanoma samples (scatter plot) are nonsynonymous mutations in genes involved in NER (marked by shape and color corresponding to each gene). Roles of these genes within the NER pathway are shown by the diagram on the right. XPG, XPF and LIG1 are core repair components; CETN2 and DDB2 are specific to global genome repair and are involved in lesion recognition. CSB is specific to TCR and is involved in recruiting NER to the stalled RNA Pol II. Samples with low (or no) reduction of somatic mutations in DHSs and carrying nonsynonymous changes in genes of core NER components also show low (or no) reduction of mutation frequency in transcribed regions, suggesting that core NER genes are responsible for both effects. NER, samples with mutations in NER genes; NER + , samples with intact NER genes.
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